Erratum: MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer. 2014 May 15;134(10):2424-2436 doi: 10.1002/ijc.28566. Epub 2013 Nov 23.

Y. J. Kim, H. S. Choi, J. Seo, J. Y. Song, S. E. Lee, M. J. Kwon, M. J. Kwon, J. Kundu, K. Jung, E. Oh, Y. K. Shin, Y. L. Choi

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)E6
JournalInternational Journal of Cancer
Volume135
Issue number7
DOIs
StatePublished - 1 Oct 2014

Cite this